Tectonic Therapeutic is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, where therapeutic options are poor or nonexistent, and new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow @TectonicTx on X (formerly Twitter) and LinkedIn.
Company profile
Ticker
TECX
Exchange
Website
CEO
Dr. Alise S. Reicin M.D., Ph.D.
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AvroBio, Inc., AVROBIO, Inc.
SEC CIK
Corporate docs
Subsidiaries
AVROBIO Australia Pty Ltd • AVROBIO Securities Corporation ...
TECX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
19 Sep 24
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Aug 24
S-8
Registration of securities for employees
21 Aug 24
8-K
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights
14 Aug 24
424B3
Prospectus supplement
14 Aug 24
10-Q
2024 Q2
Quarterly report
14 Aug 24
EFFECT
Notice of effectiveness
31 Jul 24
424B5
Prospectus supplement for primary offering
30 Jul 24
8-K
Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45
30 Jul 24
424B3
Prospectus supplement
30 Jul 24
Latest ownership filings
SC 13D/A
Atlas Venture Fund X, L.P.
28 Oct 24
SC 13D/A
SPRINGER TIMOTHY A
24 Oct 24
4
TIMOTHY A SPRINGER
24 Oct 24
SC 13D/A
SPRINGER TIMOTHY A
26 Sep 24
4
TIMOTHY A SPRINGER
26 Sep 24
SC 13G/A
FMR LLC
22 Jul 24
SC 13G
FMR LLC
10 Jul 24
SC 13G
EcoR1 Capital, LLC
1 Jul 24
SC 13D
Vida Ventures II, LLC
27 Jun 24
SC 13D
SPRINGER TIMOTHY A
26 Jun 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 185.71 mm | 185.71 mm | 185.71 mm | 185.71 mm | 185.71 mm | 185.71 mm |
Cash burn (monthly) | (no burn) | (no burn) | 3.81 mm | 9.32 mm | 4.46 mm | 3.57 mm |
Cash used (since last report) | n/a | n/a | 16.05 mm | 39.28 mm | 18.80 mm | 15.03 mm |
Cash remaining | n/a | n/a | 169.66 mm | 146.43 mm | 166.91 mm | 170.68 mm |
Runway (months of cash) | n/a | n/a | 44.6 | 15.7 | 37.4 | 47.9 |
Institutional ownership, Q2 2024
61.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 42 |
Opened positions | 42 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 86.17 bn |
Total shares | 9.00 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Timothy A Springer | 1.55 mm | $2.17 mm |
FMR | 1.08 mm | $17.75 bn |
Mcguire Terrance | 1.07 mm | $1.50 mm |
Vida Ventures II | 1.03 mm | $1.44 mm |
EcoR1 Capital | 849.14 k | $13.99 bn |
5AM Venture Management | 646.52 k | $10.65 bn |
BML Capital Management | 466.05 k | $7.68 bn |
Farallon Capital Management | 431.01 k | $7.10 bn |
Atlas Venture Life Science Advisors | 378.45 k | $6.23 bn |
ADAR1 Capital Management | 356.88 k | $5.88 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Oct 24 | Timothy A Springer | Common Stock | Buy | Acquire P | No | No | 33.59 | 300,000 | 10.08 mm | 4,096,764 |
26 Sep 24 | Timothy A Springer | Common Stock | Buy | Acquire P | No | No | 30.87 | 2,400 | 74.09 k | 3,796,764 |
26 Sep 24 | Timothy A Springer | Common Stock | Buy | Acquire P | No | No | 30.1 | 4,070 | 122.51 k | 3,794,364 |
26 Sep 24 | Timothy A Springer | Common Stock | Buy | Acquire P | No | No | 29.13 | 18,999 | 553.44 k | 3,790,294 |
26 Sep 24 | Timothy A Springer | Common Stock | Buy | Acquire P | No | No | 28.16 | 24,531 | 690.79 k | 3,771,295 |
24 Sep 24 | Timothy A Springer | Common Stock | Other | Acquire J | Yes | No | 0 | 186,134 | 0.00 | 186,134 |
24 Sep 24 | Timothy A Springer | Common Stock | Other | Acquire J | No | No | 0 | 1,054,759 | 0.00 | 3,746,764 |
24 Sep 24 | Timothy A Springer | Common Stock | Other | Dispose J | Yes | No | 0 | 1,240,893 | 0.00 | 310,223 |
20 Jun 24 | Reicin Alise | Common Stock | Grant | Acquire A | Yes | No | 0 | 124,530 | 0.00 | 124,530 |
20 Jun 24 | Reicin Alise | Common Stock | Grant | Acquire A | No | No | 0 | 166,580 | 0.00 | 166,580 |
News
Tectonic Therapeutic To Present Phase 1a Data For Its Lead Asset TX000045 At AHA 2024
22 Oct 24
Tectonic Therapeutic Announces Phase 1a Safety, Tolerability And PK/PD Results For Lead Program TX45; TX45 Was Well-tolerated With No Observed Immunogenicity, And Demonstrated A Favorable PK/PD Relationship Which Was Used To Identify Doses For The Phase 2 Clinical Trial
19 Sep 24
Wells Fargo Initiates Coverage On Tectonic Therapeutic with Overweight Rating, Announces Price Target of $55
22 Aug 24
Tectonic Therapeutic Q2 EPS $(4.34) Misses $(1.50) Estimate
14 Aug 24
Press releases
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024
22 Oct 24
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
19 Sep 24
Tectonic Therapeutic to Participate in September Investor Conferences
20 Aug 24
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights
14 Aug 24